Benin health breakthrough: moving closer to who’s pharmaceutical maturity level 3 certification

ABMed’s rigorous WHO evaluation paves way for historic health milestone

From July 6 to 9, 2026, the Agence Béninoise du Médicament et des autres produits de Santé (ABMed) underwent a meticulous assessment by a high-profile delegation of World Health Organization experts. This comprehensive audit evaluated the robustness of Benin’s pharmaceutical regulatory framework, bringing the nation one step closer to achieving the coveted Maturity Level 3 certification—a recognition reserved for systems that meet the world’s most stringent safety and efficacy standards.

A deep dive into pharmaceutical excellence

The four-day review left no stone unturned, examining every facet of ABMed’s operations. From the authorization of new medicines to post-market surveillance, pharmacovigilance protocols, and clinical trial oversight, the expert panel scrutinized compliance with international benchmarks. The findings, unveiled in Cotonou on July 9, 2026, underscore Benin’s remarkable strides in fortifying its health supply chain and safeguarding public well-being.

What does Maturity Level 3 mean for Benin?

The Maturity Level 3 designation is more than a label—it’s a testament to a nation’s ability to independently regulate pharmaceuticals with precision and integrity. Achieving this status signals that Benin’s health authorities can now ensure the availability of safe, high-quality medicines for its population while curbing the infiltration of counterfeit or substandard drugs.

This milestone also unlocks significant economic and diplomatic advantages. By aligning with WHO’s gold standard, Benin strengthens its appeal to global investors, bolsters local drug manufacturing, and positions itself as a regional hub for pharmaceutical excellence. For everyday citizens, it translates into heightened protection against health risks and greater trust in the medicines they rely on.

Years of reform culminate in success

The celebration in Cotonou was not spontaneous—it was the culmination of nearly a decade of deliberate transformation. Since 2017, Benin has overhauled its pharmaceutical sector, dismantling outdated structures and replacing them with a modern, autonomous agency (ABMed). The government also reinforced legal frameworks to clamp down on malpractice and ensure rigorous compliance with international norms.

Professor Benjamin Hounkpatin, Minister of Health, hailed the progress during the results presentation, emphasizing the tireless efforts of ABMed’s teams. He reaffirmed the state’s unwavering commitment to supporting the agency until the certification process reaches its conclusion.

West Africa’s next health leader?

If the final assessment confirms Benin’s readiness for Maturity Level 3, it will join an elite group as the second Francophone nation in West Africa to earn this distinction—trailing only Sénégal. This achievement would cement Benin’s reputation as a trailblazer in health governance, proving that visionary leadership and technical diligence can elevate even the most ambitious health goals into reality.

A new chapter for public health

The July 2026 WHO mission marks a watershed moment for Benin’s health sector. With the audit’s green light, ABMed must now finalize the last administrative steps to officially secure the certification. This journey—from aspiration to near-achievement—demonstrates that patient safety and pharmaceutical sovereignty are no longer distant ideals but an unfolding reality for Beninois communities.